Icon Plc is a leading global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in offering a comprehensive range of services that encompass a wide array of phases in the drug development process, from early-stage research and clinical trials to regulatory submissions and post-market support. With a focus on advancing healthcare innovations, Icon collaborates closely with its clients to optimize their product development strategies, improve operational efficiency, and accelerate the path to market for new therapeutic products. Their expertise encompasses various therapeutic areas, providing tailored solutions that address the specific needs of each client. Read More
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today reported its financial results for the second quarter ended June 30, 2025.
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performance scores of other large CROs, solidifying its position as a premier partner for early phase clinical studies.
ICON PLC (NASDAQ:ICLR) appears undervalued with strong profitability and reasonable financial health, making it a potential candidate for value investors in the life sciences sector.
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company’s leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer of choice.
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 24, 2025 at 8:00am ET.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company (“ICON” or “the Company”) (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 10.40 am CT.
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program.
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today reported its financial results for the first quarter ended March 31, 2025.
